Comparing the current results to its competitors, Ionis Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -40.73 %, despite the revenue increase by the most of its competitors of 2.47 %, recorded in the same quarter.
Ionis Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the RNA-targeted therapeutics market, competing with biopharmaceutical and large pharmaceutical companies developing genetic medicines and pharmaceuticals using similar technologies. Competition factors include product efficacy, safety, mechanism of action, dosing, marketing, availability, price, and reimbursement. The company identifies medicines that compete or may compete directly with its marketed and late-stage products, including those beyond Phase 1 development. Specific competitor medicines include TRYNGOLZA/olezarsen and WAYLIVRA.
September 2, 2025
Olezarsen: A Revolutionary Breakthrough in Treating Hypertriglyceridemia by Ionis Pharmaceuticals Hypertriglyceridemia (HTG), characterized by elevated levels of triglycerides in the blood, poses a significant health risk for individuals worldwide. Severe hypertriglyceridemia (sHTG) can lead to acute pancreatitis, a condition that causes inflammation of the pancreas and is associated with life-threatening complications if not managed effectively. In addition, moderate hypertriglyceridemia is a contributing factor for atherosclerotic cardiovascular disease (ASCVD), which remains a leading cause of morbidity and mortality globally. Amidst this context, Ionis Pharmaceuticals development of olezarsen marks a pr...
Publicly Traded Peers of Ionis Pharmaceuticals Inc
Inmune Bio Inc Share Performance
+13.71%
One Year
Inmune Bio Inc
Profile
Inmune Bio Inc is a biotechnology company that focuses on developing innovative therapies for treating cancer and neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to develop novel drug candidates targeting specific proteins involved in immune regulation and inflammation. They aim to license or partner their drug candidates with pharmaceutical companies for further development and commercialization, potentially generating revenue through licensing agreements or royalties.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pharming Group N.V. operates on a business model focused on the development, production, and commercialization of innovative therapeutic products for the treatment of rare diseases and unmet medical needs. The company primarily generates revenue by selling its approved products in various geographic markets and through strategic collaborations with pharmaceutical partners. Pharming Group N.V. also engages in research and development activities to expand its product pipeline and explore potential new treatments.
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Sources:
Ionis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ionis Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
